August 5th 2025, 7:00pm
TAMs may help predict response to PD-1 inhibitors in metastatic clear cell kidney cancer, Dr. Berkay Simsek reported at the 2025 Kidney Cancer Summit.
July 24th 2025, 4:00pm
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.
July 23rd 2025, 4:00pm
Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.
July 23rd 2025, 1:00pm
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
July 22nd 2025, 4:00pm
Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes.
July 21st 2025, 8:00pm
Q-TWiST may help patients with advanced kidney cancer and their doctors weigh treatment options by focusing on quality of life, not just disease control.
July 21st 2025, 7:00pm
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.
July 21st 2025, 1:00pm
Dr. Ari Hakimi highlighted how tumor profiling and molecular markers are expanding access to precision-based trials for kidney cancer.
July 20th 2025, 6:00pm
Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.
July 20th 2025, 2:00pm
Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell carcinoma, a type of kidney cancer.
Why Leaving a Breast Cancer Legacy Matters to Me
How Does Colorectal Cancer Screening Prevent and Detect Cancer?
TAR-200 Eliminates Bladder Cancer in 82% of Patients
GLP-1 Therapy Linked to Improved Outcomes in Polycythemia Vera